行情

FGEN

FGEN

纤维蛋白原
NASDAQ

实时行情|Nasdaq Last Sale

34.12
-1.78
-4.96%
盘后: 34.12 0 0.00% 16:24 04/07 EDT
开盘
37.10
昨收
35.90
最高
37.85
最低
34.11
成交量
64.90万
成交额
--
52周最高
54.60
52周最低
22.65
市值
30.03亿
市盈率(TTM)
-35.3173
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测FGEN价格均价为62.71,最高价位85.00,最低价为38.00。

EPS

FGEN 新闻

更多
  • Hedge Funds Were Selling FibroGen Inc (FGEN) Before The Coronavirus
  • Insider Monkey · 03/27 19:52
  • Biotech stocks have held up better than the broader market and these five are potential winners
  • MarketWatch · 03/24 21:23
  • Here's What Analysts Are Forecasting For FibroGen, Inc. After Its Full-Year Results
  • Simply Wall St. · 03/04 12:07
  • After coronavirus shutdown, S.F. drugmaker reopens China plants in time for major product push
  • American City Business Journals · 03/03 22:50

所属板块

生物技术和医学研究
-2.89%
制药与医学研究
-0.82%

热门股票

代码
价格
涨跌幅

FGEN 简况

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
展开

微牛提供FibroGen Inc(NASDAQ-FGEN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的FGEN股票新闻,以帮助您做出投资决策。